Most Recent
Swiss pharmaceutical company Actelion has brought a fourth patent infringement case over plans to launch a generic version of its blood pressure drug in Australia -- against Lupin unit Generic Health -- after firing off cases against three other drug makers.
Engineering group Sandvik Mining and Construction has prevailed in defence of a patent application for rotary drill technology used for underground mining.
Cipla Australia wants an undertaking it intends to give pharma company Actelion over plans to launch a generic version of a blood pressure drug to be shielded from rivals Arrotex, Nova Pharmaceuticals and MSN Laboratories, as those companies battle patent infringement claims.
The High Court has agreed to hear Otsuka's appeal of a decision that revoked its Abilify patent extension, which Otsuka argued would “lead to a groundswell of court proceedings”.
The Full Federal Court has upheld a decision revoking Otsuka Pharmaceuticals’ patent extension for an injectable version of antipsychotic drug Abilify, finding the patent expired last year.
Samsung Bioepis has successfully opposed Janssen's bid to patent a monoclonal antibody to treat ulcerative colitis, but an IP Australia delegate has given the J&J-owned company a chance to fix its application.
Abbey Animal Health has appealed its loss in a suit seeking to invalidate rival Virbac's patent for an antiparasitic drug.
Abbey Animal Health has managed only a “pyrrhic victory" in a patent case against rival Virbac over an antiparasitic drug, and must withdraw its Levamox Duo product from the market, a court has found.
Explosives company Dyno Nobel is appealing a court's dismissal of its case seeking to invalidate patents owned by rival Orica for a wireless detonation device.
Otsuka Pharmaceuticals is challenging a decision revoking its patent for an injectable version of antipsychotic drug Abilify.